LOXO-195 is a potent and selective TRK inhibitor designed to overcome acquired resistance that may emerge in patients receiving larotrectinib (LOXO-101) or multikinase inhibitors with anti-TRK activity.
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. 
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. 
 A.Drilon, et al, Cancer Discov., 2017, 7(9), pp 963-972.
Not classified as a hazardous substance or mixture
NONH for all modes of transport
Sales limitations may apply.
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.